Loading clinical trials...
Loading clinical trials...
Phase I, Double-blind, Randomized, Placebo-controlled Trial in Healthy Volunteers to Examine Safety, Tolerability, Plasma Pharmacokinetics of TMC589337&TMC589354 After Increasing Single Oral Doses & in an Open-label Part After Different Repeated Doses in Combination With Single Oral Dose of TMC310911
Conditions
Interventions
TMC589337 40 mg
TMC589337 100 mg
+15 more
Locations
1
Netherlands
Utrecht, Netherlands
Start Date
May 1, 2009
Primary Completion Date
October 1, 2009
Completion Date
October 1, 2009
Last Updated
October 28, 2016
NCT06694805
NCT04142047
NCT07428330
NCT07225530
NCT06665646
NCT05897099
Lead Sponsor
Tibotec Pharmaceuticals, Ireland
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions